Dr. Bindra is the Principal Investigator of the Phase 1 trial assessing the safety and determining the maximum tolerated dose of the T-type calcium channel blocker mibefradil combined with hypofractionated radiation therapy in subjects with recurrent glioblastoma.
Dr. Lester-Coll will present the abstract entitled Mibefradil Dihydrochoride with Hypofractionated Radiation for Recurrent Glioblastoma: Preliminary Results of a Phase I Dose Expansion Trial in an oral scientific session; the abstract has also been selected as one of the few abstracts to be discussed at the 2016 Best of ASTRO meeting to be held November 11-12 in Fort Lauderdale, Florida. The Best of ASTRO meeting will offer only the most relevant and highly influential abstracts from the 2016 Annual Meeting.
“We are encouraged by these preliminary results supporting our belief in mibefradil’s potential to become a well-tolerated treatment for patients with aggressive solid cancers such as glioblastoma,” stated Cavion President and CEO Andrew Krouse. Cavion is currently planning a Phase 1 trial of mibefradil in patients newly diagnosed with glioblastoma.
About Cavion LLC
Cavion LLC is a privately held clinical stage platform pharmaceutical company creating therapies engaging the T-type calcium channel (Cav3) for the treatment of neurologic and oncologic diseases. The T-type calcium channel is an emerging molecular target for cancer and thalamocortical dysrhythmia diseases.
Cavion is co-sponsoring a Phase 1 trial (NCT02202993) of the T-type calcium channel blocker mibefradil combined with hypofractionated radiation therapy for the treatment of recurrent glioblastoma multiforme with the Yale University Comprehensive Cancer Center. A multi-site NCI Adult Brain Tumor Consortium-sponsored Phase 1b clinical trial (NCT01480050) of mibefradil administered with temozolomide in brain cancer has completed enrollment. Cavion is currently planning a clinical trial of mibefradil in newly diagnosed brain cancer and intends to launch its first neurology clinical trial in 2017.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Cavion LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.
Contacts
Cavion LLC
Andrew Krouse, 434-200-8442
[email protected]
www.cavionpharma.com
